Copyright Reports & Markets. All rights reserved.

Global Viral and Non-viral Vector Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Viral and Non-viral Vector by Type
    • 1.3.1 Overview: Global Viral and Non-viral Vector Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Viral and Non-viral Vector Consumption Value Market Share by Type in 2025
    • 1.3.3 AAV
    • 1.3.4 Lentiviruses
    • 1.3.5 Retroviruses
    • 1.3.6 Adenoviruses
    • 1.3.7 DNA Plasmids
    • 1.3.8 Others
  • 1.4 Global Viral and Non-viral Vector Market by Application
    • 1.4.1 Overview: Global Viral and Non-viral Vector Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Pharmaceutical and Biopharmaceutical Companies
    • 1.4.3 Academics and Research Institutes
    • 1.4.4 Others
  • 1.5 Global Viral and Non-viral Vector Market Size & Forecast
  • 1.6 Global Viral and Non-viral Vector Market Size and Forecast by Region
    • 1.6.1 Global Viral and Non-viral Vector Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Viral and Non-viral Vector Market Size by Region, (2021-2032)
    • 1.6.3 North America Viral and Non-viral Vector Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Viral and Non-viral Vector Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Viral and Non-viral Vector Market Size and Prospect (2021-2032)
    • 1.6.6 South America Viral and Non-viral Vector Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Viral and Non-viral Vector Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Thermo Fisher Scientific
    • 2.1.1 Thermo Fisher Scientific Details
    • 2.1.2 Thermo Fisher Scientific Major Business
    • 2.1.3 Thermo Fisher Scientific Viral and Non-viral Vector Product and Solutions
    • 2.1.4 Thermo Fisher Scientific Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.2 Oxford BioMedica
    • 2.2.1 Oxford BioMedica Details
    • 2.2.2 Oxford BioMedica Major Business
    • 2.2.3 Oxford BioMedica Viral and Non-viral Vector Product and Solutions
    • 2.2.4 Oxford BioMedica Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Oxford BioMedica Recent Developments and Future Plans
  • 2.3 Lonza
    • 2.3.1 Lonza Details
    • 2.3.2 Lonza Major Business
    • 2.3.3 Lonza Viral and Non-viral Vector Product and Solutions
    • 2.3.4 Lonza Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Lonza Recent Developments and Future Plans
  • 2.4 GENEWIZ
    • 2.4.1 GENEWIZ Details
    • 2.4.2 GENEWIZ Major Business
    • 2.4.3 GENEWIZ Viral and Non-viral Vector Product and Solutions
    • 2.4.4 GENEWIZ Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 GENEWIZ Recent Developments and Future Plans
  • 2.5 Revvity
    • 2.5.1 Revvity Details
    • 2.5.2 Revvity Major Business
    • 2.5.3 Revvity Viral and Non-viral Vector Product and Solutions
    • 2.5.4 Revvity Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Revvity Recent Developments and Future Plans
  • 2.6 VectorBuilder
    • 2.6.1 VectorBuilder Details
    • 2.6.2 VectorBuilder Major Business
    • 2.6.3 VectorBuilder Viral and Non-viral Vector Product and Solutions
    • 2.6.4 VectorBuilder Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 VectorBuilder Recent Developments and Future Plans
  • 2.7 OBIO Technology
    • 2.7.1 OBIO Technology Details
    • 2.7.2 OBIO Technology Major Business
    • 2.7.3 OBIO Technology Viral and Non-viral Vector Product and Solutions
    • 2.7.4 OBIO Technology Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 OBIO Technology Recent Developments and Future Plans
  • 2.8 Takara Bio
    • 2.8.1 Takara Bio Details
    • 2.8.2 Takara Bio Major Business
    • 2.8.3 Takara Bio Viral and Non-viral Vector Product and Solutions
    • 2.8.4 Takara Bio Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Takara Bio Recent Developments and Future Plans
  • 2.9 GenScript Biotech
    • 2.9.1 GenScript Biotech Details
    • 2.9.2 GenScript Biotech Major Business
    • 2.9.3 GenScript Biotech Viral and Non-viral Vector Product and Solutions
    • 2.9.4 GenScript Biotech Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 GenScript Biotech Recent Developments and Future Plans
  • 2.10 Gene Chem
    • 2.10.1 Gene Chem Details
    • 2.10.2 Gene Chem Major Business
    • 2.10.3 Gene Chem Viral and Non-viral Vector Product and Solutions
    • 2.10.4 Gene Chem Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Gene Chem Recent Developments and Future Plans
  • 2.11 Geno Meditech
    • 2.11.1 Geno Meditech Details
    • 2.11.2 Geno Meditech Major Business
    • 2.11.3 Geno Meditech Viral and Non-viral Vector Product and Solutions
    • 2.11.4 Geno Meditech Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Geno Meditech Recent Developments and Future Plans
  • 2.12 PackGene Biotech
    • 2.12.1 PackGene Biotech Details
    • 2.12.2 PackGene Biotech Major Business
    • 2.12.3 PackGene Biotech Viral and Non-viral Vector Product and Solutions
    • 2.12.4 PackGene Biotech Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 PackGene Biotech Recent Developments and Future Plans
  • 2.13 VIROVEK
    • 2.13.1 VIROVEK Details
    • 2.13.2 VIROVEK Major Business
    • 2.13.3 VIROVEK Viral and Non-viral Vector Product and Solutions
    • 2.13.4 VIROVEK Viral and Non-viral Vector Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 VIROVEK Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Viral and Non-viral Vector Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Viral and Non-viral Vector by Company Revenue
    • 3.2.2 Top 3 Viral and Non-viral Vector Players Market Share in 2025
    • 3.2.3 Top 6 Viral and Non-viral Vector Players Market Share in 2025
  • 3.3 Viral and Non-viral Vector Market: Overall Company Footprint Analysis
    • 3.3.1 Viral and Non-viral Vector Market: Region Footprint
    • 3.3.2 Viral and Non-viral Vector Market: Company Product Type Footprint
    • 3.3.3 Viral and Non-viral Vector Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Viral and Non-viral Vector Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Viral and Non-viral Vector Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Viral and Non-viral Vector Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Viral and Non-viral Vector Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Viral and Non-viral Vector Consumption Value by Type (2021-2032)
  • 6.2 North America Viral and Non-viral Vector Market Size by Application (2021-2032)
  • 6.3 North America Viral and Non-viral Vector Market Size by Country
    • 6.3.1 North America Viral and Non-viral Vector Consumption Value by Country (2021-2032)
    • 6.3.2 United States Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Viral and Non-viral Vector Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Viral and Non-viral Vector Consumption Value by Type (2021-2032)
  • 7.2 Europe Viral and Non-viral Vector Consumption Value by Application (2021-2032)
  • 7.3 Europe Viral and Non-viral Vector Market Size by Country
    • 7.3.1 Europe Viral and Non-viral Vector Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 7.3.3 France Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Viral and Non-viral Vector Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Viral and Non-viral Vector Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Viral and Non-viral Vector Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Viral and Non-viral Vector Market Size by Region
    • 8.3.1 Asia-Pacific Viral and Non-viral Vector Consumption Value by Region (2021-2032)
    • 8.3.2 China Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 8.3.5 India Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Viral and Non-viral Vector Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Viral and Non-viral Vector Consumption Value by Type (2021-2032)
  • 9.2 South America Viral and Non-viral Vector Consumption Value by Application (2021-2032)
  • 9.3 South America Viral and Non-viral Vector Market Size by Country
    • 9.3.1 South America Viral and Non-viral Vector Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Viral and Non-viral Vector Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Viral and Non-viral Vector Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Viral and Non-viral Vector Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Viral and Non-viral Vector Market Size by Country
    • 10.3.1 Middle East & Africa Viral and Non-viral Vector Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Viral and Non-viral Vector Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Viral and Non-viral Vector Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Viral and Non-viral Vector Market Drivers
  • 11.2 Viral and Non-viral Vector Market Restraints
  • 11.3 Viral and Non-viral Vector Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Viral and Non-viral Vector Industry Chain
  • 12.2 Viral and Non-viral Vector Upstream Analysis
  • 12.3 Viral and Non-viral Vector Midstream Analysis
  • 12.4 Viral and Non-viral Vector Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Viral and Non-viral Vector market size was valued at US$ 998 million in 2025 and is forecast to a readjusted size of US$ 2311 million by 2032 with a CAGR of 12.9% during review period.
    Viral and non-viral vectors are delivery systems used to transfer genetic material into cells for therapeutic or research purposes. Viral vectors are modified viruses engineered to carry and deliver specific genes, taking advantage of their natural ability to infect cells. Common examples include adenoviruses, lentiviruses, and adeno-associated viruses (AAV). Non-viral vectors, on the other hand, are synthetic or naturally derived systems that do not rely on viruses. These include liposomes, nanoparticles, electroporation, and plasmid DNA. While viral vectors offer high efficiency in gene delivery, non-viral vectors are often preferred for their lower immunogenicity, easier production, and enhanced safety profiles.
    This report is a detailed and comprehensive analysis for global Viral and Non-viral Vector market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Viral and Non-viral Vector market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Viral and Non-viral Vector market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Viral and Non-viral Vector market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Viral and Non-viral Vector market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Viral and Non-viral Vector
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Viral and Non-viral Vector market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher Scientific, Oxford BioMedica, Lonza, GENEWIZ, Revvity, VectorBuilder, OBIO Technology, Takara Bio, GenScript Biotech, Gene Chem, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Viral and Non-viral Vector market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    AAV
    Lentiviruses
    Retroviruses
    Adenoviruses
    DNA Plasmids
    Others
    Market segment by Application
    Pharmaceutical and Biopharmaceutical Companies
    Academics and Research Institutes
    Others
    Market segment by players, this report covers
    Thermo Fisher Scientific
    Oxford BioMedica
    Lonza
    GENEWIZ
    Revvity
    VectorBuilder
    OBIO Technology
    Takara Bio
    GenScript Biotech
    Gene Chem
    Geno Meditech
    PackGene Biotech
    VIROVEK
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Viral and Non-viral Vector product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Viral and Non-viral Vector, with revenue, gross margin, and global market share of Viral and Non-viral Vector from 2021 to 2026.
    Chapter 3, the Viral and Non-viral Vector competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Viral and Non-viral Vector market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Viral and Non-viral Vector.
    Chapter 13, to describe Viral and Non-viral Vector research findings and conclusion.

    Buy now